Frank Simon, MD
Internal Medicine · Louisville, KYNPI 1407852221
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (49.3%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 37 manufacturers reported payments, led by Boehringer Ingelheim at 53.2% of the total. Reporting peaked in 2019 at $6,907 and has fallen 70.5% since, to $2,038 in 2025. Among internal medicine clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 444 payments — averaging $48.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$11K
- GSK$2K
- Regeneron Healthcare Solutions, Inc.$2K
- AstraZeneca$1K
- AbbVie$728
- Amgen$539
- plus $4K from 31 others
What the payments were for
- Consulting fees$1171%
- Speaking & faculty fees$10,44048%
- Travel & lodging$3201%
- Food & beverage$10,62849%
- Education$340%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 32 | $11,456 |
| GSK | 101 | $2,254 |
| Regeneron Healthcare Solutions, Inc. | 72 | $1,682 |
| AstraZeneca | 40 | $1,317 |
| AbbVie(2 entities) | 42 | $728 |
| Amgen | 23 | $539 |
| Phathom Pharmaceuticals, Inc. | 5 | $509 |
| Bayer | 18 | $431 |
| Grifols USA, LLC | 20 | $407 |
| Sanofi | 4 | $251 |
| Biohaven Pharmaceutical Holding Company Ltd. | 10 | $225 |
| Covis Pharma GmbH | 9 | $209 |
| Pfizer | 10 | $197 |
| Biohaven Pharmaceuticals, Inc. | 3 | $166 |
| Optinose US, Inc. | 8 | $142 |
| Novartis | 6 | $122 |
| Teva Pharmaceuticals USA, Inc. | 7 | $102 |
| Sanofi-aventis U.S. LLC | 2 | $100 |
| Axsome Therapeutics, Inc. | 1 | $97 |
| Blueprint Medicines Corporation | 4 | $79 |
| Supernus Pharmaceuticals, Inc. | 5 | $72 |
| Genentech USA, Inc. | 3 | $67 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $60 |
| Azurity Pharmaceuticals, Inc. | 2 | $53 |
| Shield Therapeutics Inc | 2 | $31 |
| Octapharma USA, Inc. | 1 | $30 |
| DJO, LLC | 1 | $29 |
| Upsher-smith Laboratories LLC | 1 | $24 |
| Sunovion Pharmaceuticals Inc. | 2 | $22 |
| Insulet Corporation | 1 | $22 |
| Verona Pharma, Inc. | 1 | $19 |
| Hologic Sales And Service, LLC | 1 | $19 |
| LEO Pharma Inc. | 1 | $18 |
| Viatris Specialty LLC | 1 | $17 |
| Kaleo, Inc. | 1 | $17 |
| Galderma Laboratories, L.p. | 1 | $14 |
| Novo Nordisk | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$21,539 in reported general payments places this provider in the 95th percentile of 1,284 internal medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 64 | $265,553 |
| CutaquigImmun Glob G(Igg)-Hipp/Maltose | 22 | $187,315 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 180 | $184,988 |
| Spiriva HandihalerTiotropium Bromide | 63 | $69,409 |
| Breo ElliptaFluticasone/Vilanterol | 77 | $59,809 |
| NucalaMepolizumab | 15 | $55,763 |
| Spiriva RespimatTiotropium Bromide | 28 | $30,239 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 238 | $29,845 |
| EliquisApixaban | 24 | $29,190 |
| DuleraMometasone/Formoterol | 48 | $28,442 |
| Emgality PenGalcanezumab-Gnlm | 27 | $27,346 |
| JardianceEmpagliflozin | 24 | $27,111 |
| OzempicSemaglutide | 25 | $25,930 |
| Advair HfaFluticasone Propion/Salmeterol | 42 | $25,757 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $25,393 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Nucala, Incruse Ellipta, Anoro Ellipta | $2,254 | $323,815311 claims |
| Octapharma USA, Inc.Cutaquig | $30 | $187,31522 claims |
| Boehringer IngelheimSpiriva Respimat, Jardiance | $11,456 | $57,35052 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,317 | $50,49775 claims |
| PfizerEliquis | $197 | $29,19024 claims |
| Novo NordiskOzempic | $11 | $25,93025 claims |
| AbbVieQulipta | $728 | $12,90012 claims |
| Teva Pharmaceuticals USA, Inc.Qnasl | $102 | $3,88114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,284 internal medicine providers in Kentucky.
Other internal medicine in Louisville
- Robert SasserLouisville$62K
- Kelley McIntyreLouisville$48K
- Lal TanwaniLouisville$38K
- Mark WilliamsLouisville$33K
- Scott YoungLouisville$24K
- Walter BruningLouisville$22K
- Brian ParadowskiLouisville$20K
- Suresh NairLouisville$20K
- Yiyi TsaiLouisville$19K
- Keith CarterLouisville$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.